Luther Burbank Corporation Announces First Quarter 2022 Earnings Release and Conference Call Dates

Written by Customer Service on April 8, 2022. Posted in Public Companies.

SANTA ROSA, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Luther Burbank Corporation (the “Company”) (NASDAQ: LBC), the holding company for Luther Burbank Savings (the “Bank”), announced today that it will release its financial results as of and for the quarter ended March 31, 2022 after the market closes on Tuesday, April 26, 2022. Simone Lagomarsino, President and Chief Executive Officer of Luther Burbank Corporation, and Laura Tarantino, Executive Vice President and Chief Financial Officer, will host a conference call on Wednesday, April 27, 2022 at 8:00 AM (PT) to discuss the Company’s results for the period. Analysts, investors, and the general public may listen to a discussion of the Company’s quarterly performance and a question/answer session by using the phone number or live webcast link listed below. The webcast will include...

Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors

Written by Customer Service on April 8, 2022. Posted in Public Companies.

– Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy – – Rate of eligible MAGE-A4 expression was 67% for synovial sarcoma, and ranged from 20%-35% for squamous cell lung, bladder, esophagogastric junction, ovarian, head and neck, and esophageal cancers- PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 08, 2022 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from the multinational, multicenter, screening protocol (NCT02636855) at the American Association for Cancer Research (AACR) annual meeting in a poster entitled “Identifying MAGE-A4-Positive Tumors for SPEAR T-Cell Therapies in HLA-A*02–Eligible Patients”. “This large clinical dataset continues building the...

Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance

Written by Customer Service on April 8, 2022. Posted in Public Companies.

First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate superior performance to the only clinical-stage competitor Monotherapy activity and broad combination potential Investigational New Drug (IND) application cleared; clinical trial to commence LEXINGTON, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced the first presentation of preclinical data from AGEN1571 – a novel anti-ILT2 antibody designed to modulate tumor-associated macrophages, T, NK and NKT cells. These data are being presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 8-12 in New Orleans, LA. “The...

iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022

Written by Customer Service on April 8, 2022. Posted in Public Companies.

Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients treated with an anti-TIGIT antibody In preclinical studies and in blood samples from patients with advanced cancers, treatment with EOS-448 results in a reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functions WATERTOWN, Mass. and GOSSELIES, Belgium, April 08, 2022 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of potentially differentiated immuno-oncology therapeutics for patients, today announced a presentation featuring preclinical and clinical analyses supporting...

Proactive news headlines including Tesla, Nextech AR, CULT Food Science, Agra Ventures, Guardforce AI and O3 Mining

Written by Customer Service on April 8, 2022. Posted in Mergers And Acquisitions.

New York , April 08, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Tesla’s Musk promises Cybertruck and Optimus robot next year click here Kenorland options Separation Lithium Project to Double O Seven Resources click here Nextech AR teams with Bothwell Cheese to launch human holograms on product labels click here Guardforce AI partners with Hong Kong’s Blue Pin for hotel robotic solutions upgrades click here CULT Food Science announces OTCQB Venture Market listing click here Universal Ibogaine eyeing resumption of operations after Kelburn Recovery Centre flood click here Citi analyst says there’ll be “much more than enough oil” despite Russia cuts click here Agra Ventures welcomes Health Canada’s...

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022

Written by Customer Service on April 8, 2022. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2022. “The data we presented at this year’s AACR meeting highlight the breadth and diversity of our scientific efforts, as we continue to expand our ability to deliver off-the-shelf cell therapies with the potential to disrupt the cancer treatment landscape,” said James Trager, PhD, Chief Scientific Officer of Nkarta. “Our research activities are designed to extend the capabilities of NK cells, to lay the groundwork for further pipeline...

Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors

Written by Customer Service on April 8, 2022. Posted in Public Companies.

The recommended phase 2 dose was determined at 480 mg AFM24 has demonstrated a well-managed safety profile Pharmacodynamic activity was observed at doses of 160 mg and higher The maximum tolerated dose was not reached and the dose escalation continues at 720 mg For the broad clinical AFM24 program, patients are recruited in three studies, two of which are combination studies, in 7 indications HEIDELBERG, Germany, April 08, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced data from the dose escalation phase of the phase 1/2a study with the Company’s Innate Cell Engager (ICE®) AFM24 as monotherapy at the Annual Meeting of the American Association of Cancer Research (AACR)....

Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting

Written by Customer Service on April 8, 2022. Posted in Public Companies.

– Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and duration of response compared to chemotherapy alone – SHANGHAI, China, and REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the results of the prespecified final progression-free survival (“PFS”) analysis and the interim overall survival (“OS”) analysis of the JUPITER-02 study (NCT03581786), a pivotal Phase 3 trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”). The JUPITER-02 results are summarized in a poster presentation at the annual meeting of the American Association for Cancer Research (“AACR”). In...

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

Written by Customer Service on April 8, 2022. Posted in Public Companies.

– Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – – IND or equivalent filings planned for two new product candidates in 2022, including masked anti-CD137 antibody with Fc engineering and masked anti-CD47 antibody, designed to enhance both safety and efficacy – SAN DIEGO and SUZHOU, China, April 08, 2022 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced preclinical data showcasing the potential first and best-in-class profile of new antibody candidates. Data are being presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in New Orleans, Louisiana from April 8-13, 2022. Posters are available in...

Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)

Written by Customer Service on April 8, 2022. Posted in Public Companies.

– First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 advanced cancer patients in 2030 – Findings also identify highest frequency of TSC1 alterations in bladder, kidney, and lung squamous cell cancers, while TSC2 alterations have the highest frequency in hepatobiliary, ovarian, and soft tissue sarcomas LOS ANGELES, April 08, 2022 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of a poster (#5799) at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 8-13, 2022 in New Orleans, LA. The research that was presented...

Day: April 8, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice